...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine
【24h】

Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine

机译:仙岛及其几何异构性对临床常规治疗药物监测的分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Sunitinib malate, an oral multi-targeted tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma, gastrointestinal stromal tumor, and well-differentiated pancreatic neuroendocrine tumors, has been identified as a potential candidate for therapeutic drug monitoring approach. Nevertheless, the development of an analytical assay suitable for clinical application for the quantification of the plasma concentration of sunitinib and its active metabolite, N-desethyl sunitinib, is limited by its Z/E isomerization when exposed to light. Several LC–MS/MS methods already published require protection from light during all sample handling procedures to avoid the formation of E-isomer, which makes them not suitable for clinical practice.In order to obtain a simple and fast procedure to reconvert the E-isomer, formed during sample collection and treatment without light protection, and, thus, to have only Z-isomer peak to quantify, we studied the Z/E photodegradation with special attention to the condition allowing the reverse reaction in plasma matrix.After 30?min of light exposure, the E-isomer maximum percentage of both the analytes was reached (44% of E-sunitinib and 20% of E-N-desethyl sunitinib; these percentages were calculated with respect to the sum of E?+?Z). Moreover, the formation of the E-isomer increased up to 20% after lowering the pH of the solution. Since the reverse reaction takes place when the pre-exposed solution is placed in dark, we followed the E to Z-isomer kinetics into the autosampler. The conversion rate was very slow when the autosampler was set at 4?°C (after 4?h the mean percentages of E-isomer were 50% for sunitinib and 22% for N-desethyl sunitinib). The reconversion rate was considerably accelerated with the increasing of the temperature: incubating the analytical solution in a heated water bath for 5?min at 70?°C we obtained the quantitative (99%) reconversion of the E- to the Z-isomer. No effect of concentration was observed, while the presence of acids inhibited the reconversion.Based on these results, a simple and fast procedure was setup to quantitatively reconvert the E-isomer formed during sample collection and processing without light protection into its Z-form thus leading to a single peak to quantify. The application of this additional step allows to develop a LC–MS/MS method suitable to clinical practice, due to its practicality and speed.
机译:Sunitinib苹果酸盐,批准用于治疗转移性肾细胞癌,胃肠区间肿瘤和良好分化的胰腺神经内分泌肿瘤的口腔多靶向酪氨酸激酶抑制剂已被鉴定为治疗药物监测方法的潜在候选者。然而,适用于临床应用的分析测定用于定量Sunitinib的血浆浓度及其活性代谢物N-脱乙基·桑尼替尼的临床应用,在暴露于光线时受其Z / E异构化的限制。已经公布的几种LC-MS / MS方法需要保护在所有样品处理过程中的光线,以避免形成E-ISOMER,这使得它们不适合临床实践。为了获得简单快速的程序来重新转换E-在样品收集和处理期间形成的异构体,没有光保护,因此,仅具有Z-异构体峰来量化,我们研究了Z / E光降解,特别注意允许等离子体矩阵中的逆反应的条件。30?近曝光,达到两种分析物的E-异构体的最大百分比(e-unitinib的44%和20%的eN-脱乙基锡;这些百分比相对于e≤+ z)的总和计算。此外,在降低溶液的pH后,E-异构体的形成增加了20%。由于当预先暴露的溶液在黑暗中置于暗中时,我们将e〜Z-异构体动力学置入自动进样器中。当自动进样器设定为4℃时,转化率非常慢(4?H后E-异构体的平均百分比为Sunitinib的50%,对于N-脱乙基瑞替尼的22%)。随着温度的增加,重新转化率可大幅加速:在70℃下孵育在加热的水浴中的分析溶液5Ω·min,我们得到了Z-异构体的定量(99%)重新转化。没有观察到浓度的影响,而酸的存在抑制了这些结果的重新转化。基于这些结果,设置了简单且快速的程序,以定量地重新转换在样品收集过程中形成的E-异构体,而不会进入其Z形式的Z形式而无光保护。导致单个峰值量化。该附加步骤的应用允许由于其实用性和速度,可以开发适合于临床实践的LC-MS / MS方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号